Overview
Schroder Capital Global Innovation Trust (formerly Schroder UK Public Private Trust : SUPP, and before that Woodford Patient Capital Trust : WPCT) aims to achieve long-term capital growth by investing in a diversified portfolio of 30-40 highly innovative companies on an upward trajectory, wherever they may be in the world.
Initially, the fund was distinguished by being the largest new issue of an investment trust at the time of launch and by having an unusual fee structure whereby the manager would only receive performance fees and no basic management fee. Later, the trust became embroiled in the collapse of Woodford Investment Management. Schroders were appointed managers on 13 December 2019. Under Schroders, the management fee is 1.0% a year on market capitalisation up to £600m and 0.8% above that. There is a performance fee too but this doesn’t kick in until the end of 2022.
You can access the fund’s website here.
You can view our interviews with the company’s Fund Managers below:
1st October 2021: Tim Creed – Weekly Show
Fundamentals
Price
Research History
-
26 Apr 2024
QuotedData’s Investment Companies Quarterly Review – First quarter of 2024
First quarter of 2024 Investment Companies | Quarterly roundup | April 2023 Kindly sponsored by abrdn Equity rally belies difficult quarter for sector 2024 started on strong footing, with global equities (as measured by the MSCI All Countries World Index) rallying 9.2% over the first three months (in sterling terms). However, while there some standouts […]
-
17 Oct 2023
QuotedData’s Investment Companies Quarterly Review – Third Quarter 2023
Third quarter of 2023 Investment Companies | Quarterly roundup | October 2023 Kindly sponsored by abrdn ‘Uncomfortable’ Following a fast start to the first half of the year, globally equities took a breather in Q3, as markets assessed the implications of the worst bond sell-off in a generation. Yields on 10-year US treasuries and UK […]
-
13 Oct 2023
QuotedData’s Investment Companies Roundup – October 2023
October 2023 Monthly roundup | Investment companies Kindly sponsored by abrdn Winners and losers in September 2023 September was defined by the ongoing US bond selloff, with global markets trending down in sympathy. Investment trust returns were negative on average for the month, although several sectors still achieved positive returns. The Royalties sector was the […]
-
13 Oct 2022
QuotedData’s Investment Companies Quarterly Review – Third Quarter 2022
Third quarter of 2022 Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Piling on the misery In the face of rising inflation, exacerbated by the war in Ukraine, central bankers have condemned for their relative inaction. However, in the third quarter of 2022, they stepped up a gear. Last month’s economic and political roundup […]
-
01 Oct 2021
Interview with Tim Creed from Schroder UK Public Private
In this week’s show, James Carthew talked to Tim Creed of Schroder UK Public Private If you were looking for the first part of QuotedData’s show, focused on the roundup of the week’s news, click here If there is a guest speaker you’d particularly like to hear from, please email us. Additionally, if you would […]
-
19 May 2021
QuotedData’s Spring Webinar Series – Private Equity playback
On 19th May 2021, QuotedData hosted the second of three Spring webinars. This webinar was focused on Private Equity and included presentations and Q&As from 4 investment companies’ managers, covering different aspects of this area. We would like to thank all of our speakers and attendees for joining us. Click on the links below to watch […]
-
15 Oct 2020
QuotedData's Growth Strategies Conference - playback
On the 14th October 2020 we hosted our Growth Strategies Conference webinar. The event showcased 4 investment trust managers investing across a range of investment themes with an overriding focus on growth. We would like to thank all our speakers and our attendees for joining us. Click below to watch the individual managers’ presentations – […]
-
14 Jul 2020
QuotedData’s Investment Companies Quarterly Review – Second Quarter 2020
Investment Companies Quarterly Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents In this issue Performance data Positive movers Negative movers Discounts and premiums Getting more expensive Getting cheaper Money in and out Money in Money out Major news stories Upcoming Events New research Guide The legal bit When the going gets […]
-
07 Jul 2020
QuotedData’s Investment Companies Roundup – July 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents New research Performance data Discounts and premiums Money in and out Major news stories Income Events Guide Appendix – Performance by sector full list New research Here is a list of research we published over June: CQS New City High Yield – […]
-
07 Feb 2020
QuotedData’s Investment Companies Roundup – February 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Major news stories Income Events Guide New research Here is a list of research we published over January: An annual overview note on Shires Income (SHRS) “Shires Income (SHRS) will […]
-
24 Jan 2020
QuotedData’s Investment Companies Annual Review - 2019
In this issue The sector at the end of 2019 Performance data Performance by sector and fund Money in and out of the sector Money in and out of existing funds Money coming into existing funds Money going out of existing funds Liquidations, de-listings and trading cancellations Significant rating changes Major news stories Outlook for […]
-
10 Jan 2020
QuotedData’s investment companies roundup – January 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Income Events New research Here is a list of research we published over December: An update note on BlackRock Throgmorton (THRG) “BlackRock Throgmorton continues to lead its peer group in […]
-
06 Dec 2019
QuotedData’s investment companies roundup – December 2019
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Income Events New research Here is a list of research we published over November: An initiation note on Henderson High Income “We have initiated coverage on Henderson High Income (HHI). Since […]
-
12 Nov 2019
QuotedData’s investment companies roundup – November 2019
Investment Companies Roundup Kindly sponsored by Baillie Gifford New research Over October, we published notes on Pacific Horizon, Seneca Global Income & Growth, Premier Global Infrastructure, Polar Capital Global Financials, Ecofin Global Utilities and Infrastructure, Aberdeen Standard European Logistics Income and Herald. Additionally, as part of our enhanced coverage of the property sector, we launched […]
-
15 Oct 2019
Investment companies quarterly roundup – Third quarter 2019
Investment Companies Quarterly Roundup Kindly sponsored by Baillie Gifford New research Over the third quarter, we published notes on India Capital Growth, Jupiter Emerging & Frontier Income, Montanaro European Smaller Companies, JLEN Environmental Assets, Civitas Social Housing, JPMorgan Russian Securities, International Biotechnology Trust, Aberdeen Emerging Markets, Seneca Global Income & Growth, Standard Life Investments Property Income […]
-
07 Oct 2019
QuotedData’s investment companies roundup – October 2019
Investment Companies Roundup Kindly sponsored by Baillie Gifford New research Over September, we published notes on India Capital Growth, Jupiter Emerging & Frontier, International Biotechnology Trust, JPMorgan Russian Securities, Civitas Social Housing, Montanaro European Smaller Companies and JLEN Environmental Assets. We also launched a monthly real estate roundup, beginning with reviews of August and September. In […]
-
07 Oct 2019
QuotedData’s economic roundup – October 2019
Economic & Political Roundup Kindly sponsored by Polar Capital and Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you […]
-
11 Sep 2019
QuotedData’s investment companies roundup – September 2019
Investment Companies Roundup Kindly sponsored by Baillie Gifford New research Over August, we published notes on Aberdeen Emerging Markets and JLEN Environmental Assets . You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – appetite for risk was generally down in August, as […]
-
07 Aug 2019
QuotedData’s investment companies roundup – August 2019
Investment Companies Roundup New research Over July, we published notes on CQS New City High Yield, BlackRock Throgmorton, Strategic Equity Capital, Seneca Global Income & Growth, CG Asset Management, Standard Life Investments Property Income and Aberdeen New Dawn. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – appetite […]
-
12 Jul 2019
Quarterly investment companies roundup – Second quarter 2019
Quarterly investment companies roundup – Second quarter 2019 QuotedData news Global equities re-found momentum in June after a cautious April and May. How much longer this ten-year bull market can sustain itself continues to be the subject of much debate. The prospect of interest rate cuts in the US has re-invigorated sentiment for the time […]
-
05 Jul 2019
QuotedData’s investment companies roundup – July 2019
Investment Companies Roundup New research Over June, we published notes on CQS Natural Resources Growth and Income, Standard Life Private Equity and Shires Income. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – there was a greater appetite for risk in June as […]
-
07 Jun 2019
QuotedData’s investment companies roundup – June 2019
Investment Companies Roundup New research Over May, we published notes on Shires Income, Standard Life Private Equity and The North American Income Trust. You can read all these notes by clicking on the links above or by visiting www.quoteddata.com. In this issue Performance data – it was notable that risk appetite was down in May as renewed […]
-
16 Oct 2018
Quarterly Investment Companies Roundup – Third Quarter 2018
Quarterly Investment Companies Roundup – Third Quarter 2018 Global equities delivered positive returns over the third quarter of 2018. This was principally because of strength in the US market. Political uncertainty and concerns about global trade held back other regions. Generally, government bond yields rose over the quarter. The UK equity market fell as the Bank of […]
-
12 Oct 2018
QuotedData’s investment companies roundup – October 2018
QuotedData’s investment companies roundup – October 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of August 2018. Kindly sponsored by Baillie Gifford. Money raised and returned in September Trian Investors 1 is a new fund that will adopt […]
-
14 Sep 2018
QuotedData’s investment companies roundup – September 2018
QuotedData’s investment companies roundup – September 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of August 2018. Kindly sponsored by Baillie Gifford. Money raised and returned in August GRIT Real Estate Income floated on the UK Stock Exchange in […]
-
11 Jul 2018
QuotedData’s investment companies roundup – July 2018
QuotedData’s investment companies roundup – July 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of June 2018. Kindly sponsored by Baillie Gifford. July Investment Companies Roundup Money raised and returned in June Newcomer to the market, Yew Grove […]
-
11 May 2018
QuotedData’s investment companies roundup – May 2018
QuotedData investment companies roundup – May 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of April 2018. Kindly sponsored by Baillie Gifford. India Capital Growth has experience a rebound in performance in the past month, as […]
-
18 Apr 2018
QuotedData’s investment companies roundup – April 2018
QuotedData investment companies roundup – April 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of March 2018. Kindly sponsored by Baillie Gifford. Stock markets have suffered their first meaningful fall for nearly two years. At the quarter end, […]
-
13 Mar 2018
QuotedData's investment companies roundup - March 2018
QuotedData investment companies roundup – March 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of February 2018. Kindly sponsored by Baillie Gifford. Equity markets continued to run up in early February, supported by strong corporate earnings […]
-
10 Jan 2018
QuotedData investment companies roundup – January 2018
QuotedData investment companies roundup – January 2018 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of December 2017. Kindly sponsored by Baillie Gifford. January Investment Companies Roundup Winners and losers in December Infrastructure India’s share price […]
-
11 Dec 2017
QuotedData investment companies roundup – December 2017
QuotedData investment companies roundup – December 2017 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of November 2017. Kindly sponsored by Baillie Gifford. December Investment Companies Roundup Money raised and returned in November There were no […]
-
10 Nov 2017
QuotedData investment companies roundup – November 2017
QuotedData investment companies roundup – November 2017 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of October 2017. Kindly sponsored by Baillie Gifford. November Investment Companies Roundup Globalworth Real Estate’s discount was eliminated after it announced […]
-
14 Sep 2017
QuotedData investment companies roundup – September 2017
QuotedData investment companies roundup – September 2017 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of August 2017. Kindly sponsored by Baillie Gifford. September Investment Companies Roundup Winners and losers in August Ashmore Global’s […]
-
08 Nov 2016
QuotedData investment companies roundup – November 2016
Our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of October 2016. november-investment-companies-roundup-2
News
-
19 Nov 2018
Woodford Patient Capital updates on three investments
Woodford Patient Capital updates on three investments – has released some news on Immunocore, Mission Therapeutics and Spin Memory. Immunocore Immunocore has entered into a new partnership with Genentech, part of the Roche Group, to expand an existing discovery collaboration. As part of the agreement, Genentech will pay Immunocore $100 million in upfront and near-term […]
-
21 Sep 2018
Woodford Patient Capital writes up value of Industrial Heat
Woodford Patient Capital writes up value of Industrial Heat – Woodford Patient Capital has added 8p to its NAV by writing up the value of Industrial Heat by 357%. This is now valued at $112.9m, which represents an increase of 8.02p per share of WPCT compared to the NAV published on Thursday 20 September 2018, […]
-
10 Sep 2018
Crystal Amber reports on a good year
Crystal Amber reports on a good year – The activist fund, Crystal Amber (CRS) has delivered its full annual report for the year ending 30 June 2018. Positive performance The NAV per share rose by 19.7% over the reporting period. NAV total return for the year was 22.8%. This compares well when compared with the performance of the reference benchmark, the Numis […]
-
30 Aug 2018
IP Group-backed Genomics raises £25m in a Series B
IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals. Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]
-
22 Aug 2018
WPCT takes profits on Autolus post IPO share price rise
WPCT takes profits on Autolus post IPO share price rise Woodford Patient Capital Trust (WPCT) appears to have taken some profits on its investment in the high-flying second generation CAR-T therapy company, Autolus Therapeutics, through a partial sale of its recently-boosted stake, according to an analysis of trust’s shareholdings in July reported this morning. This is […]
-
21 Aug 2018
WPCT-backed Immunocore enters Phase I with lead GSK project
WPCT-backed Immunocore enters Phase I with lead GSK project Woodford Patient Capital Trust (WPCT)-backed Immunocore has started a Phase I study of IMCnyeso, the lead engineered T cell product under its collaboration with GlaxoSmithKline (GSK), for a range of cancers. The 63-patient Phase I/II study will assess ImmTAC in patients with non-small cell lung cancer (NSCLC), […]
-
16 Aug 2018
WPCT avoids losses on Woodford backed Abzena
WPCT avoids losses on Woodford-backed Abzena Woodford Investment Management will have to take a second painful hit on one of its major biotech investments in less than a week, after the UK-based drug discovery services company Abzena agreed to a low-ball private equity takeout today after seeing a sustained share price decline. This deal follows the […]
-
14 Aug 2018
WPCT set to record £33m gain on Sensyne Health
WPCT set to record £33m gain on Sensyne Health IPO Woodford Patient Capital Trust (WPCT) looks set to record a £33m gain and a 45x return on its original shareholding in the UK healthcare AI firm Sensyne Health, as a result of the company’s IPO on the London stock exchange. Sensyne, which was founded and […]
-
10 Aug 2018
Woodford finally closes chapter on failed Vernalis investment
Woodford finally closes chapter on failed Vernalis investment Neil Woodford’s eponymous Patient Capital Trust (WPCT) will have to look forward to receiving just £1.8m for the 30.6m shareholding – acquired in 2015 for £18.5m – in Vernalis, the UK biotech whose failed endeavour to break into the US cough/cold market led to it being put up […]
-
07 Aug 2018
Investment Trust Insider on Syncona
Investment Trust Insider on Syncona James Carthew: the problem with Syncona’s big premium Regular readers of this column will have realised that I often have as much of a problem with investment trusts trading on very high premiums as I do with trusts trading on very wide discounts. I explained a couple of weeks ago […]
-
03 Aug 2018
Tekla Healthcare top specialist fund performer in July
Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]
-
03 Aug 2018
Arix remains highly geared to Autolus value
Arix remains highly geared to Autolus value Arix Bioscience’s 8% investment in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, now accounts for more than half of the value of its investments, some 25% of its NAV and almost 30% of its stockmarket value, according to calculations by Marten & Co. Arix is by far […]
-
24 Jul 2018
Autolus jumps to top of Woodford Patient Capital
Autolus jumps to top position in Woodford Patient Capital Trust Woodford Patient Capital Trust (WPCT)’s stake in Autolus, the UK second generation CAR-T therapy company, rose by six places to top position in the portfolio in June, according to WPCT’s latest factsheet. The rise reflects Autolus’ recent IPO, which was priced at a valuation considerably above […]
-
05 Jul 2018
Autolus IPO boosts WPCT to top of specialist trust league in June
Autolus IPO boosts WPCT to top of specialist trust league in June The Nasdaq float of Autolus, one its top ten investee companies, boosted Woodford Patient Capital Trust (WPCT) to top position in the performance league table of biotech/healthcare specialist investment trusts for the month of June, both in terms of price and NAV total return. […]
-
25 Jun 2018
Arix, Syncona and WPCT bank gains after Autolus "pops" on Nasdaq IPO
Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) should be able to record some sizeable NAV gains this month, as previously highlighted in earlier Quoteddata.com articles, on the back of a revaluation to market value of their respective holdings in the common portfolio […]
-
21 Jun 2018
US biotech IPO market faces key test after record five pricings
US biotech IPO market faces key test after record five pricings The currently buoyant US market for biotech new issues faces a key test, after a record five companies priced Nasdaq offerings in a single day. The success of those listings in the immediate after-market is likely to be important gauge of the overall health […]
-
20 Jun 2018
WPCT still at bottom of bio specialist trust league in May
WPCT still at bottom of bio specialist trust league in May Neil Woodford’s eponymous Patient Capital Trust (WPCT) has once again ranked at the bottom of the performance league table of biotech/healthcare specialist investment trusts maintained by Marten & Co in the month of May, both in terms of price and NAV total return. This is […]
-
14 Jun 2018
Arix, Syncona and WPCT look set to reap gains on pending Autolus IPO
Arix, Syncona and WPCT look set to reap gains on pending Autolus Nasdaq IPO Three LSE-listed health/biotech venture capital investment firms – Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) – should see a nice boost to their NAV if Autolus, the UK-based CAR-T cell company completes its proposed Nasdaq IPO. Autolus is a portfolio company for […]
-
22 May 2018
WPCT sees £43m drop in value of Prothena stake
WPCT sees £43m drop in value of Prothena stake value Woodford Patient Capital Trust (WPCT) lost £43m on its investment in Prothena last month, following the failure of the company’s NEOD001 for AL amyloidosis, according to an analysis of its portfolio by Marten & Co. Having for some time last year been WPCT’s largest investment, […]
-
10 May 2018
Prothena drags WPCT to bottom of performance league table in April
Prothena drags WPCT to bottom of performance league table in April The fall in the value of its large investment in Prothena on negative results from two late-stage trials last month had a predictable effect on Woodford Patient Capital (WPCT)’s performance among the biotech-specialist closed end funds this year, although its relative underperformance extends over […]
-
23 Apr 2018
Prothena blow-up leaves Woodford Patient Capital reeling
Prothena blow-up leaves Woodford Patient Capital reeling Neil Woodford’s controversial and high-profile investment in Prothena (NASDAQ:PRTA) and its development programme for AL Amyloidosis has failed, costing the Woodford Patient Capital Investment Trust (WPCT) an estimated £50m based on the average $40/share acquisition cost of its large shareholding. Prothena’s US-listed stock has fallen by 68% this […]
-
20 Apr 2018
WPCT investors nervously await key Prothena data readout
WPCT investors nervously await key Prothena data readout Investors in Woodford Patient Capital Trust (WPCT) should watch for a key data readout from US-listed but Ireland-based Prothena (NASDAQ:PRTA) expected anytime in the next few weeks, which could potentially add up to 5% to the value of the trust in event of a positive result but reduce […]
-
03 Apr 2018
WPCT gets surprise boost up trust leaguetable from Prothena deal
WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]
-
21 Mar 2018
WPCT gets boost from Prothena-Celgene deal
WPCT gets boost from Prothena-Celgene deal Shares in Woodford Patient Capital Trust (WPCT) have risen by almost 10% this morning to 78p on news of a partnership announced after US markets closed last night between its largest investee company, Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG). The partnership will develop new therapies for neurodegenerative disease, including Alzheimer’s, and […]
-
20 Mar 2018
WPCT should see benefit from Oxford Nanopore fundraising
WPCT should see benefit on Oxford Nanopore fundraising Neil Woodford-managed Woodford Patient Capital Trust (WPCT) has finally generated something positive for its long suffering investors, with the fund likely to be able to take a roughly £8m fair value gain on its holding in Oxford Nanopore, following a new £100m fundraising by its UK-based investee […]
-
06 Mar 2018
UK Life science VC investors cheer planned IPO of Autolus
UK Life science VC investors cheer planned IPO of Autolus Three high-profile UK life science investors – Syncona (SYNC), Arix Bioscience (ARIX) and Woodford Patient Capital Trust (WPCT) – could benefit from the possible US IPO of the engineered T-cell therapy company, Autolus, following that company’s disclosure yesterday of a filing of a confidential draft F1 submission. All three investors hold […]
-
02 Mar 2018
Swiss trusts top performers among bio sector specialists in Feb
Swiss trusts top performers among bio sector specialists in Feb – Switzerland’s HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S) were the best performing biotech/pharma specialist investment trusts in February and indeed were the only ones of the 13 monitored by Marten & Co to have recorded any increase in NAV (in sterling terms) in the month. However, […]
-
22 Feb 2018
WPCT sees small decline in Jan NAV but greater share price fall
WPCT sees small decline in Jan NAV but greater share price fall Struggling Neil Woodford-managed Woodford Patient Capital Trust (WPCT) reported a small, ~0.6% decline in NAV in January, but has since seen a larger 11% decline in share price this month as investors have become increasingly concerned about its poor long-term performance and outlook. The decline […]
-
09 Feb 2018
Swiss biotech trusts resilient after recent sell-off
Swiss biotech trusts resilient after recent sell-off – Swiss-listed biotech investment trusts, HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S), have fared by far the best among all the sector specialist closed-end collective vehicles in the wake of the global market sell-off in recent days. All 13 trusts in the group monitored by Marten & Co have seen a fall […]
-
23 Jan 2018
HBM Healthcare tops biotech trust league in 2017
HBM Healthcare tops biotech trust league in 2017 Swiss-listed HBM Healthcare Investments (HBMN.S) can claim to have been the best performing biotech-specialist closed-end fund in 2017, according to an analysis by Marten & Co. The CHF1.1bn trust run by Swiss healthcare investment specialist HBM saw its share price rise from CHF99 to CHF134 last year […]
-
22 Dec 2017
Prothena drag on Woodford Patient Capital
Prothena drag on Woodford Patient Capital A 45% fall in the value of its large shareholding in Prothena since the end of the third quarter seems to have been the main factor behind a decline in the value of Woodford Patient Capital Trust (WPCT) over the same period, according to the trust’s latest monthly update. WPCT’s shares have […]
-
18 Dec 2017
Investment Trust Insider on Biotech
Investment Trust Insider on Biotech – inspired by the launch of our biotech news service on QuotedData, I wrote something for Citywire that looks at some of the exciting stories that have been published just in the last couple of weeks. James Carthew: biotech boom boosts generalist trusts This week I am returning to the […]
-
18 Dec 2017
US analysts target Woodford Patient Capital investees
US analysts target key Woodford Patient Capital investees The Neil Woodford-managed biotech/tech investment trust, Woodford Patient Capital Trust (WPCT), is finding itself under increasing pressure, with analysts at two separate US firms calling into question its two largest investments, Prothena (15.6% of NAV at 30 September ) and Oxford Nanopore (8.9%). Ireland-based but Nasdaq-listed Prothena […]
-
12 Dec 2017
UK CAR-T firm Autolus provides update at ASH conference
UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]
-
12 Sep 2017
Investment Trust Insider on The People's Trust
The People’s Trust, Daniel Godfrey’s long-trailed investment trust, launched its initial public offer (IPO) on Friday. It is aiming to raise £125 million. The fund intends to produce ‘better returns for you and a better impact on society’. There won’t be a huge dividend, a yield of about 1.8% is forecast, and this may curb […]
-
31 Jul 2017
Better year for Growth pool in F&C Managed Portfolio
Better year for Growth pool in F&C Managed Portfolio – F&C Managed Portfolio has published results for the year ended 31 May 2017. The NAV total return (i.e. adding dividends paid to capital performance) was 24.5% for the Income shares and 26.4% for the Growth shares. This compares with the 24.5% total return for the All-Share […]
-
21 Apr 2017
More patience required for Woodford Patient Capital shareholders
Woodford Patient Capital says that 2016 was a challenging year, with its net asset value declining modestly from 97.37p to 93.24p. Meanwhile, the share price moved from a 3.7 per cent premium to net asset value at the end of 2015, to a slight discount of -2.4 per cent at the end of the period, […]
-
15 Nov 2016
Woodford investment trust gets Trump boost
The Woodford Patient Capital trust has enjoyed a 4 per cent boost to its NAV following the election of Donald Trump to the White House. The Woodford fund was among the top-10 investment trusts on the day after the US election, with many of the best performing being focussed on biotech. read more here
-
14 Nov 2016
Why Neil Woodford is celebrating a Trump victory
I don’t know whether fund management legend Neil Woodford was in favour of Trump or Clinton, or wished a plague on both their houses, and nor do I care (writes Harvey Jones of Motley Fool). However, Donald Trump’s shock victory has given Mr Woodford something to celebrate, by applying much-needed balm to his Achilles’ heel. read more […]
-
08 Nov 2016
Woodford trust falls into worst performers list in October
The £733m Woodford Patient Capital trust appeared in the top ten worst performing funds in NAV terms in October according to the latest research from investment company analysts QuotedData. The trust, ran by star manager Neil Woodford, was down 5.1% for the month, making it the fifth worst performing fund in NAV terms in the […]
-
06 Oct 2016
If it is good enough for Neil Woodford... peer-to-peer trusts can yield up to 10% - but are they worth the risk?
In today’s low interest rate world, investment trusts are struggling to match the income payouts they have maintained in recent years. Read more: http://www.thisismoney.co.uk/money/diyinvesting/article-3813416/Peer-peer-investment-trusts-offer-yields-10-worth-risk.html#ixzz4MJTrYHYS
-
04 Aug 2016
Woodford Patient Capital beefs up board after disappointing H1
Woodford Patient Capital says its portfolio declined in value by 10.8 per cent over the first half of 2016 and the company’s shares ended the period at a modest discount of 3.1 per cent. Two new non-executive directors have been brought onto the Board following consultation with shareholders. The new non-executive directors have specific investment trust experience. […]
-
05 Jul 2016
Crystal Amber asks for sale of Northgate
On 4 July 2016, it was disclosed that Crystal Amber Fund Limited had acquired a disclosable interest of 3 per cent of the issued share capital of Northgate. In September 2012, Crystal Amber invested in Northgate and following successful engagement, exited the position in April 2015. Since then, Northgate’s share price has fallen by approximately 50%. […]
-
21 Jun 2016
Woodford comments on Circassia
In its latest blog, Woodford Patient Capital has commented on the dramatic fall in the price of its largest investment, Circassia. You can read the blog in full here. “[Circassia] has this morning announced the failure of its high-profile phase III study into its cat allergy vaccine. This is undoubtedly a disappointing development. We had high […]
-
22 Mar 2016
Woodford Patient Capital suspends fund raising
Woodford Patient Capital has published its first set of results covering the period from incorporation through its launch in April last year and finishing on 31 December 2015. The net asset value of Woodford Patient Capital Trust ended the period at 97.38p per share (cum income), slightly below the issue price of 100p per share. […]
-
13 Jan 2016
Woodford Patient Capital is considering raising further capital
Woodford Patient Capital Trust, managed by Neil Woodford (pictured), has provided an update to investors which advises that the trust has now deployed the proceeds from its IPO (the trust listed on the LSE in April 2015 raising £800m) and that it has a substantial ongoing pipeline of investment opportunities. The company says that, with […]
-
03 Dec 2015
Woodford Patient Capital’s Purplebricks to list on AIM
Online estate agency, Purplebricks, has announced that it has conditionally raised £58.1m before expenses from an institutional placing for its upcoming float on AIM. The company, which is expected to list on 17 December, is expected to have an opening market capitalisation of £240.3m. Woodford Patient Capital Trust, managed by Neil Woodford (pictured) has an investment […]
-
24 Nov 2015
BACIT backed Woodford fund
BACIT Limited has announced interim results for the six months ended 30 September 2015. The return on net assets for the period was -3.28% which compares to -7.19% for the FTSE All-Share Index and -6.78% for the HFRI Fund of Funds Strategic Index. Looking at the portfolio: Equity Funds (24.9% at 30 September 2015 vs. […]
-
11 Aug 2015
Woodford Patient Capital unveils its portfolio
Woodford Patient Capital has published its first set of figures – interims covering the period from its launch until the end of June 2015. The net asset value at the end of the period was 101.86p and the share price 113.5p – putting it on a premium of 11.4%. The Board is planning to issue […]
-
22 Jul 2015
Discount trends, big names big prices
http://www.moneyobserver.com/news/21-07-2015/discount-trends-big-names-big-prices Investment trusts with big name managers saw their share prices soar over the second quarter as investors sought out the best active management.
-
20 Jul 2015
Investment trusts see largest ever new issue
QuotedData reports that the investment trust sector expanded by about GBP2.4 billion over the second quarter of 2015, taking in close to GBP2.9 billion and handing back just over GBP450 million. The firm comments that many of the funds raising money are not designed to throw off high levels of income, suggesting that investors are […]